- Home
- SKYE vs WHF Comparison
SKYE vs WHF Comparison
Compare SKYE & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- WHF
- Stock Information
- Founded
- SKYE 2012
- WHF 2011
- Country
- SKYE United States
- WHF United States
- Employees
- SKYE N/A
- WHF N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- WHF Finance Companies
- Sector
- SKYE Health Care
- WHF Finance
- Exchange
- SKYE Nasdaq
- WHF Nasdaq
- Market Cap
- SKYE 121.8M
- WHF 162.2M
- IPO Year
- SKYE N/A
- WHF 2012
- Fundamental
- Price
- SKYE $1.57
- WHF $7.03
- Analyst Decision
- SKYE Strong Buy
- WHF Hold
- Analyst Count
- SKYE 5
- WHF 4
- Target Price
- SKYE $14.75
- WHF $9.17
- AVG Volume (30 Days)
- SKYE 1.9M
- WHF 152.5K
- Earning Date
- SKYE 11-12-2025
- WHF 11-10-2025
- Dividend Yield
- SKYE N/A
- WHF 25.50%
- EPS Growth
- SKYE N/A
- WHF N/A
- EPS
- SKYE N/A
- WHF 0.15
- Revenue
- SKYE N/A
- WHF $81,499,000.00
- Revenue This Year
- SKYE N/A
- WHF N/A
- Revenue Next Year
- SKYE N/A
- WHF N/A
- P/E Ratio
- SKYE N/A
- WHF $45.74
- Revenue Growth
- SKYE N/A
- WHF N/A
- 52 Week Low
- SKYE $1.14
- WHF $6.53
- 52 Week High
- SKYE $5.96
- WHF $12.18
- Technical
- Relative Strength Index (RSI)
- SKYE 33.63
- WHF 42.07
- Support Level
- SKYE $1.31
- WHF $6.96
- Resistance Level
- SKYE $1.76
- WHF $7.25
- Average True Range (ATR)
- SKYE 0.13
- WHF 0.23
- MACD
- SKYE -0.01
- WHF 0.09
- Stochastic Oscillator
- SKYE 34.18
- WHF 68.04
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.